All In Biotech

Drug Trial Radar · NCT01178112

Trientine and Carboplatin in Advanced Malignancies

Phase I Study of Trientine and Carboplatin in Patients With Advanced Malignancies

Last checked: Nov 20, 2026Latest source record: Nov 18, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

Jul 2010

Primary completion

Aug 2014

Study completion Aug 2014

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 9, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical research study is to find the highest tolerable dose of the combination of trientine and carboplatin that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.

Conditions

  • Advanced Cancers

Interventions

  • TrientineDrug

    Starting dose 750 mg by mouth four times a day, two times with meals and two times without meals for 28 days.

  • CarboplatinDrug

    Starting dose area under curve (AUC) 4 by vein over two hours on day 1, and once every 28 days.

  • Trientine MTDDrug

    Maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2.

  • Carboplatin MTDDrug

    Maximum tolerated dose found in MTD Dose Escalation Group

  • PK TestingOther

    Blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD) of Carboplatin with TrientineTime frame: 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.